IgA nephropathy is associated with a progressive decrease in the eGFR, which leads to a substantial lifetime risk of kidney failure despite supportive therapies. Research findings from the RAINIER AIS-D08 trial are summarized in a new Quick Take video. nej.md/4iEIOh3
A visual representation of the RAINIER AIS-D08 trial, which tested whether povetacicept altered markers of nephropathy progression in IgA nephropathy.

ALT A visual representation of the RAINIER AIS-D08 trial, which tested whether povetacicept altered markers of nephropathy progression in IgA nephropathy.

Nov 10, 2026 · 6:00 PM UTC

4
11
67
12,901
RelevantRecentLikes
IgA nephropathy can look stable while kidney function slips away slowly, so changing that trajectory matters. I am curious how povetacicept holds up over years, not just on trial markers. The real test will be fewer people reaching kidney failure, and at what cost.
1
319
@NEJM
Image from fausto heredia z. (@drfherediaz)
167
Load more replies